The aim of this technology assessment, commissioned by NICE through the NIHR SR Programme as part of the NICE Single Technology Appraisal process, was to review the submission received from the Astellas on the clinical and cost-effectiveness evidence of Enzalutamide with androgen deprivation therapy (ADT) for treating metastatic hormone-sensitive prostate cancer (Xtandi®). The primary source of clinical effectiveness evidence submitted by Medtronic consisted of two phase III RCTs (ARCHES and ENZAMET) comparing Enzalutamide with ADT. The Aberdeen HTA Group acted as the Evidence Review Group (ERG) for this technology appraisal and provided an independent critique of the clinical and cost-effectiveness evidence submitted by the company. Based on the findings of the submission received from the company and the ERG’s critique, NICE will soon release appropriate clinical guidance. For more information see: https://www.nice.org.uk/guidance/indevelopment/gid-ta10488
Contacts
- Miriam Brazzelli; m.brazzelli@abdn.ac.uk